In patients co-infected with HIV and latent TB, what is a key management consideration?

• A. Delay ART until completion of TB therapy.
• B. Integrated TB therapy with ART and careful monitoring for drug interactions, especially rifampin with certain ART.
• C. Use rifampin monotherapy without ART.
• D. Start ART after TB therapy has been completed for at least one year.

Answer: (B)

Treat HIV and TB at the same time, with ART started alongside TB therapy and careful planning for drug interactions. In HIV/TB coinfection, starting ART promptly during TB treatment improves survival and immune recovery, so delaying ART until TB therapy is finished is not ideal. The tricky part is rifampin, a common TB drug that strongly induces liver enzymes and can lower levels of many antiretroviral medications. Because of this, the management plan must be coordinated: select an ART regimen that remains effective with rifampin or adjust the TB/ART regimen under supervision (for example, choosing regimens known to tolerate rifampin well). This integrated approach also means close monitoring for drug interactions, hepatotoxicity, and adherence, ensuring both infections are treated effectively.